Working... Menu

Insulin Glargine in Type 1 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00272090
Recruitment Status : Completed
First Posted : January 4, 2006
Last Update Posted : June 8, 2011
Information provided by:

Brief Summary:
The primary purpose of the protocol is to demonstrate that the new regimen (insulin glargine+regular insulin ) is no worse than the reference regimen (insulin glargine+lys-pro insulin ) in reducing the incidence of severe nocturnal hypoglycemia at the end point; the secondary purpose is to compare the two study regimens as far as the glycemic control (measured by HbA1c), the daily Mean Blood Glucose (MBG) and the mean amplitude of glycemic excursion (MAGE index), calculated on the basis of Self Monitoring Blood Glugose (SMBG) data, are concerned and to verify the safety of basal insulinization with Lantus.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Drug: Insulin glargine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 489 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Italian Experience Trial for the Implementation of the Use of Lantus in Basal - Bolus Regimen in Type I Diabetes Mellitus Patients.
Study Start Date : November 2002
Actual Primary Completion Date : December 2005
Actual Study Completion Date : December 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Primary Outcome Measures :
  1. severe nocturnal hypoglycemias will be measured throughout the study period.

Secondary Outcome Measures :
  1. HbA1c will be measured at basal and 8/16 weeks after start of treatment
  2. 8 point glucose profile will be measured during last 2 weeks before each scheduled visit
  3. severe hypoglycemias and nocturnal hypoglycemias will be measured throughout the study period.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Subjects with type 1 diabetes mellitus for more than three years
  • Subjects on multiple daily injection insulin therapy, basal-bolus scheme therapy
  • HbA1c <= 9 % (measured by central Lab, with DCCT aligned standard method)
  • Fasting C-Peptide <= 0,1nmol/L with FBG >126 mg/dl
  • Body Mass Index (BMI) < 30 kg/m2
  • Willingness to accept intensive insulin therapy
  • Ability and willingness to perform SMBG using plasma glucose meter
  • Female subjects must be postmenopausal or under adequate contraception as judged by the investigator (it may be oral contraceptives, intra-uterine device or surgical treatment) and must have a negative serum pregnancy test

Exclusion criteria:

  • Diabetes other than type 1 diabetic mellitus
  • Type 1 diabetic patients with total insulin dose >= 1 IU/kg/day
  • Serum creatinine > 1.5 mg/dl, or history of renal transplantation or current renal dialysis
  • Congestive heart failure NYHA class II
  • Acute or chronic metabolic acidosis, including diabetic ketoacidosis
  • Clinical evidence of active liver disease, or serum ALT/AST 2 times the upper limit of the normal range
  • Hypoglycemia unawareness
  • Pregnancy or lactation
  • Concomitant use of β-blockers, thiazides or systemic corticosteroids
  • More than one episode of severe hypoglycemia with seizure or coma during the past year
  • Likelihood of requiring treatment during the study period with any anti-diabetic drug other than the study drugs
  • Failure to use adequate contraception (women of current reproductive potential only)
  • Known hypersensitivity to insulin glargine, or any of the excipients
  • Malignancy except basal cell carcinoma within the last five years
  • Long lasting (> 2 weeks) treatment with systemic glucocorticoid therapy
  • Known adrenal insufficiency (interferes with hypoglycemia counter-regulation)
  • Known hemoglobinopathy or chronic anemia because it may interfere with Hb1Ac determination
  • History of substance or alcohol abuse within the last two years or current addiction to substances of abuse including ethanol
  • History of positive HIV test or Hepatitis B/C test
  • Any usage outside of the current SPC (Summary of the Product Characteristics)
  • Any clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease other than type 1 diabetic mellitus making implementation of the protocol or interpretation of the study results difficult
  • History of demonstrable micro- and macro-angiopathic complications
  • Pre-planned surgery during the study
  • Blood donation of more than 500 ml during the previous 3 months for males or 6 months for females
  • Smoker for previous 3 months
  • Receipt of an experimental drug or use of an experimental device within the 30 days prior to study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00272090

Sponsors and Collaborators
Layout table for investigator information
Study Director: PAIZIS GEORGES, MD Sanofi

Layout table for additonal information
Responsible Party: Trial Transparency Team, sanofi-aventis Identifier: NCT00272090     History of Changes
Other Study ID Numbers: HOE901_3507
First Posted: January 4, 2006    Key Record Dates
Last Update Posted: June 8, 2011
Last Verified: June 2011

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs